Overview

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb